Make no mistake, embracing biosimilars can help to build a sustainable NHS.
Indeed, biosimilars can help reduce the growing pressure on the NHS. More than 15 million people in England – about a quarter of the population – live with at least one long-term health condition, accounting for roughly 70% of health and social care spending.
Chronic diseases such as diabetes, cancer and autoimmune disorders are on the rise: diabetes affects over 5 million people; cancer prevalence in the UK is projected to increase from 3 million to 5.3 million by 2040; and autoimmune diseases impact about one in ten individuals.
These trends are largely driven by an ageing population, with those aged 65 or over projected to rise to 27% by 2072, up from 19% in 2022.
Check out the rest of the feature here
